Stockscreener 앱 받기
0.4055
5.32%
-0.0228
전일 마감가:
$0.4283
열려 있는:
$0.418
하루 거래량:
196.59K
Relative Volume:
0.36
시가총액:
$28.15M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.1566
EPS:
-2.59
순현금흐름:
$-104.11M
1주 성능:
-15.85%
1개월 성능:
-7.76%
6개월 성능:
-72.03%
1년 성능:
-74.17%
1일 변동 폭
$0.4042
$0.46
1주일 범위
$0.4042
$0.569
52주 변동 폭
$0.2601
$2.525
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
BCAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.4055 | 28.15M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World
Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World
Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times
BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan
BioAtla’s SWOT analysis: CAB platform stock faces pivotal year amid clinical trials - Investing.com Nigeria
Dimensional Fund Advisors LP Sells 86,264 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla receives Nasdaq delisting warning By Investing.com - Investing.com India
BioAtla receives Nasdaq delisting warning - Investing.com Australia
BioAtla Receives Nasdaq Non-Compliance Notice - TipRanks
HC Wainwright Issues Negative Estimate for BioAtla Earnings - Defense World
HC Wainwright Predicts BioAtla’s Q1 Earnings (NASDAQ:BCAB) - Defense World
BioAtla Inc (NASDAQ: BCAB): Is Its Value Too High Compared To Others? - Stocksregister
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Relay Therapeutics (RLAY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
BioAtla stock holds $1 target, JMP affirms Market Outperform By Investing.com - Investing.com Nigeria
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus By Investing.com - Investing.com India
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus - Investing.com Australia
Bioatla Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gaining Ground: BioAtla Inc (BCAB) Closes Lower at 0.48, Down -8.19 - DWinneX
BioAtla, Inc. (NASDAQ:BCAB) Q1 2025 Earnings Call Transcript - Insider Monkey
BioAtla Q1 2025 Earnings Call Transcript - MarketBeat
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... By GuruFocus - Investing.com Canada
BioAtla (NASDAQ:BCAB) vs. Novavax (NASDAQ:NVAX) Head-To-Head Comparison - Defense World
Bioatla, Inc. Earnings Call Highlights Clinical Success - TipRanks
BioAtla, Inc. Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations - Investing.com
BioAtla, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCAB) - Seeking Alpha
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Re - GuruFocus
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations By Investing.com - Investing.com UK
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Results | BCAB Stock News - GuruFocus
BioAtla reports Q1 EPS (26c), consensus (29c) - TipRanks
BioAtla Reports Breakthrough: Cancer Drug Triples Survival Rate vs Standard Treatment in Lung Cancer Study - Stock Titan
BioAtla, Inc. (NASDAQ:BCAB) Shares Acquired by Renaissance Technologies LLC - Defense World
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - Sete News
BioAtla Inc (BCAB) shows promising results - uspostnews.com
BioAtla Reveals Next-Gen Cancer Treatment Progress: Key Updates Coming at Citizens Conference - Stock Titan
BCAB: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
An Analysis of BioAtla Inc (BCAB)’s Potential Price Growth - knoxdaily.com
BioAtla Q1 2025 Earnings: Biotech Leader to Share Latest Cancer Treatment Progress on May 6 - Stock Titan
Bank of Montreal Can Sells 522,252 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):